Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | SUCNR1 | Q9BXA5 | 11/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | OXGR1 | Q96P68 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21314499 | 1.00 | TDP1 (0.48) | TDP1SUCNR1MEN1KMT2AL3MBTL1 | |
| SCHEMBL6265814 | 0.82 | SUCNR1 (0.53) | SUCNR1ALDH1A1OXGR1KDM4EBDKRB1 | |
| SCHEMBL24194292 | 0.81 | SUCNR1 (0.49) | SUCNR1ALDH1A1OXGR1KDM4ELMNA | |
| SCHEMBL17921405 | 0.80 | SUCNR1 (0.48) | SUCNR1ALDH1A1OXGR1KDM4ELMNA | |
| SCHEMBL20024878 | 0.79 | SUCNR1 (0.46) | SUCNR1MEN1KMT2AALDH1A1OXGR1 | |
| SCHEMBL26971219 | 0.76 | SUCNR1 (0.47) | SUCNR1MEN1KMT2AOXGR1KDM4E | |
| SCHEMBL31075741 | 0.76 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1TSHRKDM4E | |
| SCHEMBL20487944 | 0.76 | PDE10A (0.43) | TDP1SUCNR1MEN1KMT2AALDH1A1 | |
| SCHEMBL6421241 | 0.75 | MAPT (0.46) | SUCNR1ALDH1A1OXGR1BDKRB1 | |
| SCHEMBL6421236 | 0.75 | MAPT (0.46) | SUCNR1ALDH1A1OXGR1BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | TDP1 4658/4885SUCNR1 2279/4885MEN1 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.